Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Neuroinflammation has long been considered a potential contributor to neurodegenerative disorders that result in dementia. Accumulation of abnormal protein aggregates in Alzheimer’s disease, frontotemporal dementia, and dementia with Lewy bodies is associated with the activation of microglia and astrocytes into proinflammatory states, and chronic low-level activation of glial cells likely contributes to the pathological changes observed in these and other neurodegenerative diseases. The 18 kDa translocator protein (TSPO) is a key biomarker for measuring inflammation in the brain via positron emission tomography (PET). Increased TSPO density has been observed in brain tissue from patients with neurodegenerative diseases and colocalizes to activated microglia and reactive astrocytes. Several radioligands have been developed to measure TSPO density in vivo with PET, and these have been used in clinical studies of different dementia syndromes. However, TSPO radioligands have limitations, including low specific-to-nonspecific signal and differential affinity to a polymorphism on the TSPO gene, which must be taken into consideration in designing and interpreting human PET studies. Nonetheless, most PET studies have shown that increased TSPO binding is associated with various dementias, suggesting that TSPO has potential as a biomarker to further explore the role of neuroinflammation in dementia pathogenesis and may prove useful in monitoring disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726 · cited 1×
“In such a scenario, the evidence suggests that the amount of microglial activation in the second peak would continue to rise as the dementia process worsens (Calsolaro & Edison, 2016).”
BackgroundPrevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
A polarizing question: do M1 and M2 microglia exist?
Ransohoff, R. M. (2016) · Nature Neuroscience · doi:10.1038/nn.4338 · Cited by 1,573
Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.
(1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.416 · Cited by 1,331
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329
Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265 · cited 2×
“…a proposed pathogenic contributor to diffuse Lewy body disease (DLBD), which includes the aforementioned PDD and DLB. DLBD is defined by aggregated α-synuclein inclusions (i.e., Lewy bodies), which activate microglia in vitro and stimulate release of proinflammatory mediators (Zhang et al., 2005).”
BackgroundIn vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 3×
“Another small study found that four patients with progressive supranuclear palsy (PSP) displayed increased 11C-(R)-PK11195 binding in striatum, cerebellum, brainstem, thalamus, and the frontal lobe (Gerhard et al., 2006).”
BackgroundResultIn-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · cited 1×
“For instance, studies found that 11C-(R)-PK-11195 binding was increased in AD patients and correlated with clinical severity (Cagnin et al., 2001; Edison et al., 2008; Yokokura et al., 2011).”
BackgroundOffice of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration
Dickson, D. W., Bergeron, C., Chin, S. S., Duyckaerts, C., Horoupian, D., Ikeda, K., Jellinger, K., Lantos, P. L., Lippa, C. F., Mirra, S. S., et al. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.11.935 · Cited by 724 · cited 1×
“However, another study found that the distribution of tau pathology commonly seen in CBD overlapped with the location of increased binding (Dickson et al., 2002).”
BackgroundBuchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70194-7 · Cited by 564 · cited 2×
“In addition, MCI patients without evidence of amyloidopathy are less likely to have pathologically defined AD at autopsy (Vos et al., 2013), and they show less cognitive decline than amyloid-positive MCI patients (Landau, Horng, Fero, Jagust, & Alzheimer’s Adv Pharmacol.”
BackgroundHamelin, L., Lagarde, J., Dorothée, G., Leroy, C., Labit, M., Comley, R. A., de Souza, L. C., Corne, H., Dauphinot, L., Bertoux, M., et al. (2016) · Brain · doi:10.1093/brain/aww017 · Cited by 519
Edison, P., Archer, H. A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F. E., Hammers, A., Tai, Y. F., Fox, N., Kennedy, A., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.08.001 · Cited by 513 · cited 2×
“For instance, studies found that 11C-(R)-PK-11195 binding was increased in AD patients and correlated with clinical severity (Cagnin et al., 2001; Edison et al., 2008; Yokokura et al., 2011).”
BackgroundReactive Glia not only Associates with Plaques but also Parallels Tangles in Alzheimer’s Disease
Serrano-Pozo, A., Mielke, M. L., Gómez-Isla, T., Betensky, R. A., Growdon, J. H., Frosch, M. P., & Hyman, B. T. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.05.047 · Cited by 488
The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
McGeer, P. L., & McGeer, E. G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1177-7 · Cited by 467 · cited 1×
“…response is a key pathological contributor to AD (Baik, Kang, Son, & MookJung, 2016; Jin et al., 2015; Lee, McGeer, & McGeer, 2015; McGeer & McGeer, 2013; Raha et al., 2017). β-Amyloid activates microglia at physiologic concentrations (Maezawa et al., 2011), resulting in release…”
BackgroundCosenza‐Nashat, M., Zhao, M. ‐., Suh, H. ‐., Morgan, J., Natividad, R., Morgello, S., & Lee, S. C. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.01006.x · Cited by 459 · cited 3×
“Brain tissue from AD patients revealed activated microglia and reactive astrocytes, which overexpress TSPO when proximal to β-amyloid plaques (Cosenza-Nashat et al., 2009).”
BackgroundInfluentialCarter, S. F., Schöll, M., Almkvist, O., Wall, A., Engler, H., Långström, B., & Nordberg, A. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.087031 · Cited by 442 · cited 1×
“In studies, the MAO-B radioligand 11C-L-deprenyl showed greater binding in AD and MCI patients than in older controls (Carter et al., 2012; Choo, Carter, Adv Pharmacol.”
BackgroundGhosh, S., Wu, M. D., Shaftel, S. S., Kyrkanides, S., LaFerla, F. M., Olschowka, J. A., & O'Banion, M. K. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4361-12.2013 · Cited by 390
Frontotemporal dementia and its subtypes: a genome-wide association study
Ferrari, R., Hernandez, D. G., Nalls, M. A., Rohrer, J. D., Ramasamy, A., Kwok, J. B. J., Dobson-Stone, C., Brooks, W. S., Schofield, P. R., Halliday, G. M., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70065-1 · Cited by 383
Microglial activation and amyloid deposition in mild cognitive impairment: A PET study
Okello, A., Edison, P., Archer, H. A., Turkheimer, F. E., Kennedy, J., Bullock, R., Walker, Z., Kennedy, A., Fox, N., Rossor, M., et al. (2009) · Neurology · doi:10.1212/01.wnl.0000338622.27876.0d · Cited by 367
Gao, H.-M., Zhang, F., Zhou, H., Kam, W., Wilson, B., & Hong, J.-S. (2011) · Environmental Health Perspectives · doi:10.1289/ehp.1003013 · Cited by 355 · cited 2×
“The amount of activated microglia is proportional to both the number of Lewy bodies found at autopsy (Mackenzie, 2000) and, in transgenic mice, to the amount of α-synuclein and measured loss of dopaminergic neurons (Gao et al., 2011).”
BackgroundIn vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease
Kreisl, W. C., Lyoo, C. H., McGwier, M., Snow, J., Jenko, K. J., Kimura, N., Corona, W., Morse, C. L., Zoghbi, S. S., Pike, V. W., et al. (2013) · Brain · doi:10.1093/brain/awt145 · Cited by 350 · cited 4×
“…that binding was greater in amyloid-positive AD patients than in controls or than in amyloid-positive mild cognitive impairment (MCI) patients, especially in temporo-parietal regions; no difference was noted in the cerebellum, which is typically spared of pathology in AD (Kreisl et al., 2013) (Fig.”
BackgroundResultSelf-citationTranslocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects
Rupprecht, R., Rammes, G., Eser, D., Baghai, T. C., Schüle, C., Nothdurfter, C., Troxler, T., Gentsch, C., Kalkman, H. O., Chaperon, F., et al. (2009) · Science · doi:10.1126/science.1175055 · Cited by 328
Neuroinflammation in Neurodegenerative Disorders-a Review
Schain, M., & Kreisl, W. C. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0733-2 · Cited by 301
Self-citationMolecular Imaging of Microglial Activation in Amyotrophic Lateral Sclerosis
Corcia, P., Tauber, C., Vercoullie, J., Arlicot, N., Prunier, C., Praline, J., Nicolas, G., Venel, Y., Hommet, C., Baulieu, J.-L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052941 · Cited by 249 · cited 2×
“A and MAO-B are isoenzymes that metabolize neurotransmitters and xenobiotic amines via oxidative deamination (Saura et al., 1994), and hydrolysis of substrates by MAO-B results in reactive oxygen species as a by-product (Corcia et al., 2012).”
BackgroundNoninvasive Molecular Imaging of Neuroinflammation
Jacobs, A. H., Tavitian, B., & the INMiND consortium (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.53 · Cited by 245
Positron emission tomography and functional characterization of a complete PBR/TSPO knockout
Banati, R. B., Middleton, R. J., Chan, R., Hatty, C. R., Wai-Ying Kam, W., Quin, C., Graeber, M. B., Parmar, A., Zahra, D., Callaghan, P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6452 · Cited by 241
Tu, L. N., Morohaku, K., Manna, P. R., Pelton, S. H., Butler, W. R., Stocco, D. M., & Selvaraj, V. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.578286 · Cited by 239 · cited 1×
“However, recent findings in viable mice genetically depleted of TSPO have called into question its role in some of these functions (Banati et al., 2014; Morohaku et al., 2014; Selvaraj, Stocco, & Tu, 2015; Tu et al., 2014; Tu, Zhao, Stocco, & Selvaraj, 2015).”
BackgroundBaik, S. H., Kang, S., Son, S. M., & Mook-Jung, I. (2016) · Glia · doi:10.1002/glia.23074 · Cited by 234
Zürcher, N. R., Loggia, M. L., Lawson, R., Chonde, D. B., Izquierdo-Garcia, D., Yasek, J. E., Akeju, O., Catana, C., Rosen, B. R., Cudkowicz, M. E., et al. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.01.009 · Cited by 226 · cited 1×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript approaches with a different radioligand without first validating it against kinetic modeling (Bloomfield et al., 2016; Zurcher et al., 2015).”
Iannaccone, S., Cerami, C., Alessio, M., Garibotto, V., Panzacchi, A., Olivieri, S., Gelsomino, G., Moresco, R. M., & Perani, D. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.07.002 · Cited by 221 · cited 9×
“…PET studies in patients with Parkinson’s disease without dementia have mostly shown positive results (Bartels et al., 2010; Gerhard et al., 2006; Iannaccone et al., 2013; Ouchi et al., 2005), although there have been a small number of negative studies (Bartels et al., 2010; Ghadery et al.,…”
BackgroundResultInfluentialKuhlmann, A. C., & Guilarte, T. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741694.x · Cited by 215
In vivo detection of microglial activation in frontotemporal dementia
Cagnin, A., Rossor, M., Sampson, E. L., MacKinnon, T., & Banati, R. B. (2004) · Annals of Neurology · doi:10.1002/ana.20332 · Cited by 187
Yokokura, M., Mori, N., Yagi, S., Yoshikawa, E., Kikuchi, M., Yoshihara, Y., Wakuda, T., Sugihara, G., Takebayashi, K., Suda, S., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1612-0 · Cited by 174
In vivo imaging of microglial activation with [11C](R)‐PK11195 PET in progressive supranuclear palsy
Gerhard, A., Trender‐Gerhard, I., Turkheimer, F., Quinn, N. P., Bhatia, K. P., & Brooks, D. J. (2006) · Movement Disorders · doi:10.1002/mds.20668 · Cited by 171 · cited 2×
“Another small study found that four patients with progressive supranuclear palsy (PSP) displayed increased 11C-(R)-PK11195 binding in striatum, cerebellum, brainstem, thalamus, and the frontal lobe (Gerhard et al., 2006).”
BackgroundResultTREM2 is associated with increased risk for Alzheimer’s disease in African Americans
Jin, S. C., Carrasquillo, M. M., Benitez, B. A., Skorupa, T., Carrell, D., Patel, D., Lincoln, S., Krishnan, S., Kachadoorian, M., Reitz, C., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0016-9 · Cited by 153 · cited 2×
“Neuroimmune response is a key pathological contributor to AD (Baik, Kang, Son, & MookJung, 2016; Jin et al., 2015; Lee, McGeer, & McGeer, 2015; McGeer & McGeer, 2013; Raha et al., 2017).”
BackgroundYasuno, F., Kosaka, J., Ota, M., Higuchi, M., Ito, H., Fujimura, Y., Nozaki, S., Takahashi, S., Mizukami, K., Asada, T., et al. (2012) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2011.08.013 · Cited by 148 · cited 1×
“…>1.5 SD above the mean binding of controls had converted to dementia at follow-up; however, of the seven MCI patients imaged at baseline, two were lost to follow-up and one had 11C-DAA1106 binding similar to that seen in controls but still converted to dementia at follow-up (Yasuno et al., 2012).”
BackgroundInfluentialMaeda, J., Zhang, M.-R., Okauchi, T., Ji, B., Ono, M., Hattori, S., Kumata, K., Iwata, N., Saido, T. C., Trojanowski, J. Q., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3076-10.2011 · Cited by 136
Fan, Z., Okello, A. A., Brooks, D. J., & Edison, P. (2015) · Brain · doi:10.1093/brain/awv288 · Cited by 135
Suridjan, I., Pollock, B. G., Verhoeff, N. P. L. G., Voineskos, A. N., Chow, T., Rusjan, P. M., Lobaugh, N. J., Houle, S., Mulsant, B. H., & Mizrahi, R. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.1 · Cited by 132 · cited 2×
“In addition, binding with 18F-FEPPA was shown to be greater in AD patients than in controls in hippocampus and white matter regions such as internal capsule and cingulum bundle, as well as in prefrontal, temporal, parietal, and occipital cortices (Suridjan et al., 2015).”
BackgroundFörster, S., Grimmer, T., Miederer, I., Henriksen, G., Yousefi, B. H., Graner, P., Wester, H.-J., Förstl, H., Kurz, A., Dickerson, B. C., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.023 · Cited by 119
Liu, B., Le, K. X., Park, M.-A., Wang, S., Belanger, A. P., Dubey, S., Frost, J. L., Holton, P., Reiser, V., Jones, P. A., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0996-15.2015 · Cited by 114 · cited 1×
“18F-GE180, a recently developed TSPO radioligand, was reported to have increased binding in amyloid-producing transgenic mice (Brendel et al., 2016; Liu et al., 2015).”
BackgroundMicroglial activation in Parkinson’s disease using [18F]-FEPPA
Ghadery, C., Koshimori, Y., Coakeley, S., Harris, M., Rusjan, P., Kim, J., Houle, S., & Strafella, A. P. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0778-1 · Cited by 113 · cited 1×
“…PET studies in patients with Parkinson’s disease without dementia have mostly shown positive results (Bartels et al., 2010; Gerhard et al., 2006; Iannaccone et al., 2013; Ouchi et al., 2005), although there have been a small number of negative studies (Bartels et al., 2010; Ghadery et al., 2017).”
Result
Cited by
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Neuroimaging biomarkers for Alzheimer’s disease.
Márquez, F., & Yassa, M. A. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0325-5 · Cited by 289
Neuronal activity increases translocator protein (TSPO) levels
Notter, T., Schalbetter, S. M., Clifton, N. E., Mattei, D., Richetto, J., Thomas, K., Meyer, U., & Hall, J. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0745-1 · Cited by 118
Microglial Activation and Connectivity in Alzheimer Disease and Aging
Rauchmann, B., Brendel, M., Franzmeier, N., Trappmann, L., Zaganjori, M., Ersoezlue, E., Morenas‐Rodriguez, E., Guersel, S., Burow, L., Kurz, C., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26465 · Cited by 61
Metadata
- Authors
- Kreisl, W. C., Henter, I. D., & Innis, R. B.
- Venue
- Advances in Pharmacology
- Publisher
- Elsevier
- Published
- 2018
- Volume
- 82
- Pages
- 163-185
- ISSN
- 1054-3589 (ISSN-L)
- OpenAlex
- W2767448527
- Cited by
- 38
- References
- 43
- FWCI
- 17.23
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.